DSS (DSS) Registration filing summary

Company overview and business model

• Operates as a multi-segment company with businesses in packaging, biotechnology, commercial lending, and securities/investment management.

• Product Packaging segment provides custom packaging and security printing solutions, primarily in the U.S.

• Biotechnology segment includes investments and development, notably through Impact BioMedical Inc., a publicly traded subsidiary.

• Commercial Lending segment offers financing solutions such as lines of credit, equipment financing, and loan servicing.

• Securities and Investment Management segment manages interests in brokerage, investment management, and real estate platforms.

Financial performance and metrics

• Reported year-over-year revenue growth and increased printed product sales in Q1 2025.

• Completed sale of a facility for $9.5 million, using part of the proceeds to reduce debt.

• As of December 31, 2025, had $17.0 million in net intangible assets, mostly tied to Impact BioMedical.

• Significant customer concentration: one customer accounted for 29% of consolidated revenue as of December 31, 2025.

• Outstanding indebtedness includes multiple secured loans and convertible notes, with some loans in default as of the filing date.

Use of proceeds and capital allocation

• Net proceeds from the offering (estimated at $7.05 million if fully subscribed) will be used for working capital and general corporate purposes, including R&D, capital expenditures, and potential acquisitions.

• No current commitments for acquisitions or investments as of the prospectus date.

• Management has broad discretion over allocation of proceeds.